, diabetes, hypertension, CKD), cardiovascular risk, intolerance to statins, or other patients characteristics, or for primary vs. secondary prevention? observational follow-ups of RCT cohorts What is the comparative effectiveness and safety of treating to reach specific LDL-C or non-HDL-C goals or based only on initial cardiovascular risk assessment? Does this vary by patients age, gender, co-morbid conditions (e.g., diabetes, hypertension, CKD, CHF), cardiovascular risk, intolerance to statins, or other patients characteristics, or for primary vs. secondary prevention? 4 SRs and 2 RCTs What is the effectiveness and safety of intensifying treatment by adding non-statins (i.e., ezetimibe, PCSK9 inhibitor, bile acid sequestrant, niacin, fibrate or fish oils) to statins, increasing statins dose, or using lower LDL-C or non-HDL-C goals to improve cardiovascular outcomes? Does this vary by patients age, gender, co-morbid conditions (e.g., diabetes, hypertension, CKD, CHF), cardiovascular risk, intolerance to statins, or other patients characteristics, or for primary vs. secondary prevention? label extensions of RCTs Among patients at risk of CVD, including patients with dyslipidemia on statin, but who do not tolerate statin well, what is the effectiveness of various strategies (e.g., education, switching statins, use of lower doses, alternate day dosing) to improve patients tolerance to statins, adherence, or to allow statin dose increase? studies What is the safety and efficacy of stopping statins for dyslipidemia among patients who have been on a statin? 2 SRs and 1 RCT What is the cost-effectiveness of various pharmacologic (PCSK9 inhibitors, statins) and non-pharmacologic treatment? 2 SRs and 3 cost- effectiveness studies Question Number Question Number of Studies & Type of Studies What is the effectiveness (vs. placebo), comparative effectiveness (vs. another dietary supplement/nutraceutical), and safety of dietary supplements/nutraceuticals (e.g., Omega-3, red yeast rice, soluble fiber, garlic, ginger, plant sterols, green tea, niacin) on cardiovascular outcomes? 